



## Last day of trading of Series TO 1 B subscription warrants

Today, 11 June 2019, is the last day of trading of the Series TO 1 B subscription warrants that were issued in connection with Calmark Sweden AB (publ)'s ("Calmark") spring/summer 2018 issue of units prior to listing. The exercise period for the Series TO 1 B subscription warrants ends on 13 June 2019.

The Series TO 1 B subscription warrants will expire worthless if the holder does not actively subscribe for shares by 13 June 2019 at the latest, or sells the warrants no later than today, 11 June 2019. Holders are advised to contact their banks, since access times may vary.

Teaser and application form are available for download at the websites of Calmark ([www.calmark.se](http://www.calmark.se)), Sedermera Fondkommission ([www.sedermera.se](http://www.sedermera.se)) and Spotlight Stock Market ([www.spotlightstockmarket.com](http://www.spotlightstockmarket.com)), respectively.

### Financial advisor

Sedermera Fondkommission is the financial advisor and issuing agent of Calmark in connection with the exercise period for the company's Series TO 1 B subscription warrants.

### For more information regarding the subscription of Series TO 1 B subscription warrants, please contact:

Sedermera Fondkommission  
Telephone: +46 40-615 14 10  
E-mail: [info@sedermera.se](mailto:info@sedermera.se)

### For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO  
Telefon: +46 70 213 25 35  
E-post: [anna.soderlund@calmark.se](mailto:anna.soderlund@calmark.se)  
[www.calmark.se](http://www.calmark.se)

**Calmark Sweden AB** is a medical technology company developing a point-of-care (POC) analysis method with easier and faster sampling of medical conditions in newborns. The unique test platform, which consists of a reader and single-use products, is expected to be ready for launch in 2020 when three important POC tests are introduced. The WHO estimates that 1.5 billion children will be born worldwide by 2030. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter healthcare chains. In less developed healthcare systems, the product helps save lives. Calmark aims to become the global leader and ultimately to offer all relevant POC tests for the first period of life, regardless of where in the world a baby is born. Read more about Calmark [www.calmark.se/eng/home](http://www.calmark.se/eng/home).